RCS - Ondine Biomedical - Steriwave proven effective against XDR bacteria

Ondine BiomedicalAnnouncement

14/09/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230914:nRSN4860Ma&default-theme=true

RNS Number : 4860M  Ondine Biomedical Inc.  14 September 2023

14 September 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Steriwave proven highly effective against XDR bacteria

Ondine to present research demonstrating high efficacy against Extensively
Drug-Resistant (XDR) bacteria at ICPIC 2023, Geneva

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) is presenting
new research at the 2023 International Consortium on Prevention &
Infection Control (ICPIC) in Geneva, demonstrating high efficacy of its
patented photodisinfection technology against extensively drug-resistant (XDR)
bacteria. Ondine is the global leader in developing photodisinfection-based
therapies for the prevention of healthcare-associated infections.

The study demonstrates that Ondine's Steriwave™ photodisinfection technology
is highly effective (>99.99% kills in 20 seconds) against both moderately
drug-resistant (MDR) and extensively drug-resistant (XDR) pathogens.
Gram-negative bacteria, such as Escherichia coli, Pseudomonas aeruginosa,
Enterobacter cloacae, and Klebsiella pneumoniae cause many serious
healthcare-associated infections.  The research underlines the potential for
Steriwave to become a rapid, broad-spectrum, bactericidal alternative to
antibiotics.

Antimicrobial resistance (AMR) poses an urgent global public health threat
resulting in 1.27 million annual deaths worldwide, and is predicted to become
one of the largest threats to human health in the coming years.( i  (#_edn1) )
The emergence and worldwide spread of extensively drug-resistant (XDR)
microbes is highly concerning, as infections caused by these pathogens are
virtually untreatable because they are proving resistant to almost all
approved antimicrobial agents.( ii  (#_edn2) )(,( iii  (#_edn3) ))

Dr. Nicolas Loebel, Ondine's CTO and President, commented: "Overuse of
antibiotics over decades has caused adaptation in many microbes, and we now
see multidrug resistance (MDR) evolving into extensive drug resistance (XDR)
in bacteria, rendering even the most powerful combination of drugs
ineffective. We believe photodisinfection can play a significant role in
cost-effectively combatting these drug-resistant pathogens and reducing global
reliance on antibiotics.  We know of no other antimicrobial that can match
the performance, safety, and cost benefits of photodisinfection."

Ondine's Steriwave system employs patented technology that rapidly and safely
eliminates bacteria, fungi, and viruses located on human tissues. Ondine is a
previous winner of an ICPIC Innovation Award of Excellence for its clinical
and pre-clinical work demonstrating photodisinfection efficacy against
SARS-CoV-2. In 2013, Canada's Vancouver General Hospital was also awarded the
ICPIC Innovation Award of Excellence for its universal pre-surgical nasal
decolonization program using Ondine's Steriwave system, significantly reducing
post-surgical infection rates and improving outcomes for thousands of surgical
patients.

The poster presentation, "Antimicrobial Photodynamic Therapy Against
Extensively Drug-Resistant (XDR) Gram-Negative Isolates With Novel Antibiotic
Resistance Factors
(https://ondinebio.com/wp-content/uploads/2023/09/ICPIC-2023-Photodisinfection-Against-XDR-Pathogens-poster.pdf)
", is being presented at the 7(th) International Consortium on Prevention
& Infection Control (ICPIC) from 1:00 pm to 2:00 pm CET on Thursday 14
September 2023. ICPIC is a leading international conference on the prevention
of healthcare-associated infections and the control of antimicrobial
resistance around the world.

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Products beyond nasal photodisinfection include
therapies for a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.

 

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

 

 

 i  (#_ednref1) Antimicrobial Resistance Collaborators (2022). Global burden
of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet
(London, England), 399(10325), 629-655.
https://doi.org/10.1016/S0140-6736(21)02724-0

 ii  (#_ednref2) Ryding, S. "What are Extensively Drug Resistant (XDR)
Bacteria?" News Medical Life Sciences. Nov. 16, 2021.
https://www.news-medical.net/health/What-are-Extensively-Drug-Resistant-(XDR)-Bacteria.aspx
(https://www.news-medical.net/health/What-are-Extensively-Drug-Resistant-(XDR)-Bacteria.aspx)

 iii  (#_ednref3) CDC. COVID-19: U.S. Impact on Antimicrobial Resistance,
Special Report 2022. Atlanta, GA: U.S.

Department of Health and Human Services, CDC; 2022.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFEIAVISLIV